国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
JOURNAL OF INTERNATIONAL ONCOLOGY
2015年
1期
10-13
,共4页
食管肿瘤%药物疗法,联合%紫杉醇%洛铂
食管腫瘤%藥物療法,聯閤%紫杉醇%洛鉑
식관종류%약물요법,연합%자삼순%락박
Esophageal neoplasms%Drug therapy,combination%Paclitaxel%Lobaplatin
目的 观察紫杉醇联合洛铂同期放化疗治疗中晚期食管癌的近期疗效和安全性.方法 68例中晚期食管癌患者根据随机数字表法随机分为紫杉醇联合洛铂同期放化疗组(TL组)和顺铂联合5-氟尿嘧啶、亚叶酸钙同期放化疗组(PF组),放疗总剂量为60～ 70 Gy.放疗期间同步化疗2个疗程.TL组化疗剂量为紫杉醇60 mg/m2,第1天,每周1次,连用6～8周,洛铂30 mg/m2,第2天,每3周为1个周期.PF组化疗剂量为顺铂75 mg/m2,第1天,5-氟尿嘧啶500 mg/m2,第1～5天,亚叶酸钙200 mg/m2,第1～5天.结果 入组患者均可评价疗效.TL组与PF组同步放化疗结束时有效率分别为73.53％和50.00％,中位无进展生存时间分别为13.0个月和6.5个月,差异均有统计学意义(x2=4.023,P=0.040;x2 =4.512,P=0.034).两组Ⅲ～Ⅳ度恶心呕吐发生率分别为5.88％和35.29％,Ⅲ～Ⅳ度白细胞下降发生率分别为20.59％和32.35％,两组Ⅲ～Ⅳ度血小板下降发生率分别为32.35％和8.82％,差异均有统计学意义(x2=8.500,P=0.003;x2=3.200,P =0.041;x2=6.710,P=0.016).两组Ⅲ～Ⅳ度食管炎发生率分别为11.76％和17.65％,差异无统计学意义(x2=1.450,P =0.493).结论 TL组治疗中晚期食管癌近期疗效肯定,不良反应可耐受,可以考虑作为中晚期食管癌的治疗方案.
目的 觀察紫杉醇聯閤洛鉑同期放化療治療中晚期食管癌的近期療效和安全性.方法 68例中晚期食管癌患者根據隨機數字錶法隨機分為紫杉醇聯閤洛鉑同期放化療組(TL組)和順鉑聯閤5-氟尿嘧啶、亞葉痠鈣同期放化療組(PF組),放療總劑量為60～ 70 Gy.放療期間同步化療2箇療程.TL組化療劑量為紫杉醇60 mg/m2,第1天,每週1次,連用6～8週,洛鉑30 mg/m2,第2天,每3週為1箇週期.PF組化療劑量為順鉑75 mg/m2,第1天,5-氟尿嘧啶500 mg/m2,第1～5天,亞葉痠鈣200 mg/m2,第1～5天.結果 入組患者均可評價療效.TL組與PF組同步放化療結束時有效率分彆為73.53％和50.00％,中位無進展生存時間分彆為13.0箇月和6.5箇月,差異均有統計學意義(x2=4.023,P=0.040;x2 =4.512,P=0.034).兩組Ⅲ～Ⅳ度噁心嘔吐髮生率分彆為5.88％和35.29％,Ⅲ～Ⅳ度白細胞下降髮生率分彆為20.59％和32.35％,兩組Ⅲ～Ⅳ度血小闆下降髮生率分彆為32.35％和8.82％,差異均有統計學意義(x2=8.500,P=0.003;x2=3.200,P =0.041;x2=6.710,P=0.016).兩組Ⅲ～Ⅳ度食管炎髮生率分彆為11.76％和17.65％,差異無統計學意義(x2=1.450,P =0.493).結論 TL組治療中晚期食管癌近期療效肯定,不良反應可耐受,可以攷慮作為中晚期食管癌的治療方案.
목적 관찰자삼순연합락박동기방화료치료중만기식관암적근기료효화안전성.방법 68례중만기식관암환자근거수궤수자표법수궤분위자삼순연합락박동기방화료조(TL조)화순박연합5-불뇨밀정、아협산개동기방화료조(PF조),방료총제량위60～ 70 Gy.방료기간동보화료2개료정.TL조화료제량위자삼순60 mg/m2,제1천,매주1차,련용6～8주,락박30 mg/m2,제2천,매3주위1개주기.PF조화료제량위순박75 mg/m2,제1천,5-불뇨밀정500 mg/m2,제1～5천,아협산개200 mg/m2,제1～5천.결과 입조환자균가평개료효.TL조여PF조동보방화료결속시유효솔분별위73.53％화50.00％,중위무진전생존시간분별위13.0개월화6.5개월,차이균유통계학의의(x2=4.023,P=0.040;x2 =4.512,P=0.034).량조Ⅲ～Ⅳ도악심구토발생솔분별위5.88％화35.29％,Ⅲ～Ⅳ도백세포하강발생솔분별위20.59％화32.35％,량조Ⅲ～Ⅳ도혈소판하강발생솔분별위32.35％화8.82％,차이균유통계학의의(x2=8.500,P=0.003;x2=3.200,P =0.041;x2=6.710,P=0.016).량조Ⅲ～Ⅳ도식관염발생솔분별위11.76％화17.65％,차이무통계학의의(x2=1.450,P =0.493).결론 TL조치료중만기식관암근기료효긍정,불량반응가내수,가이고필작위중만기식관암적치료방안.
Objective To evaluate the short-term efficacy and safety of concurrent chemoradiotherapy (CCRT) with paclitaxel and lobaplatin for advanced esophageal cancer.Methods Sixty-eight patients with advanced esophageal cancer were randomly divided into two groups according to random number table method:CCRT with paclitaxel and lobaplatin (TL group) and CCRT with DDP and 5-Fu (PF group).The CCRT regimen included radiotherapy at a total dose of 60-70 Gy,and concurrent paclitaxel 60 mg/m2 on d1,a fraction per week for 6-8 weeks,lobaplatin 30 mg/m2 on d2,a fraction per 3 weeks (TL group),and concurrent DDP 75 mg/m2 on d1,5-Fu 500 mg/m2,d1-5,CF 200 mg/m2,d1-5 (PF group).Results All 68 patients were evaluable for response.The response rates were 73.53％ in TL group and 50.00％ in PF group,the median progression-free survival were 13.0 months in TL group and 6.5 months in PF group.There were significant differences (x2 =4.023,P =0.040; x2 =4.512,P =0.034).The incidence rates of Ⅲ-ⅣW degree nausea and vomiting,granulocytopenia and thrombocytopenia were 5.88％ and 35.29％,20.59％ and 32.35％,32.35％ and 8.82％,and the differences were statistically significant (x2 ＝ 8.500,P =0.003 ; x2 =3.200,P =0.041; x2 =6.710,P =0.016).The incidence rates of Ⅲ-Ⅳ degree esophagitis in the two groups were 11.76％ and 17.65％,and there was no significant difference (x2 =1.45,P =0.493).Conclusion The efficacy of TL group in the treatment of advanced esophageal cancer is excellent,and all toxicities are well tolerated.So this protocol may be considered a main regimen in the treatment of advanced esophageal cancer.
